RxDoctor Payments Data

Kimberly Koerner, APRN

Nurse Practitioner · Reno, NVNPI 1992936272

Payments from drug & device makers

$719in general payments, 2019–2025

Across 26 payments — averaging $27.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$115
  • Nalu Medical, Inc.$104
  • Nevro Corp.$82
  • AbbVie$71
  • Collegium Pharmaceutical, Inc.$50
  • Globus Medical$50
  • plus $248 from 9 others

What the payments were for

  • Food & beverage$719100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$719 in reported general payments places this provider in the 65th percentile of 933 nurse practitioner providers in Nevada.

See all nurse practitioner providers in Nevada

Medicare billing

Part B allowed, 2024
$181,923
Medicare patients
293
Services billed
3,387

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,464$34,242
Xtampza ErOxycodone Myristate39$27,362
ProliaDenosumab15$24,800
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen510$14,264
MovantikNaloxegol Oxalate35$13,749
Oxycodone Hcl543$11,426
Gabapentin460$8,160
Morphine Sulfate ErMorphine Sulfate337$5,678
Pregabalin256$5,462
Buprenorphine21$4,943
Lidocaine30$3,093
Diclofenac Sodium63$2,589
Tramadol Hcl334$2,029
Cyclobenzaprine Hcl192$1,865
Tizanidine Hcl189$1,829

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$50$27,36239 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 933 nurse practitioner providers in Nevada.

Other nurse practitioner in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →